Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1643 1645 1646
This examiner grants 43% of resolved cases
Carol Ann Chase is an examiner in Tech Center 1600 and Art Unit 1600. The examiner has 61 resolved cases. This number of resolutions provides a focused look at the examiner's prosecution history. The data set allows practitioners to observe the examiner's approach to patentability and the typical outcomes for applications in this specific technology area.
The allowance rate is 42.6 percent. This figure indicates the proportion of resolved cases that have resulted in a patent grant. The median days to allowance is 1315. This duration represents the time required for an application to move through the examination process to a successful conclusion. Applicants can use this figure to plan their intellectual property timelines and budget for the prosecution phase.
The interview lift is 84.7 percent. This indicates that an interview is associated with a significant increase in the probability of an allowance. The positive lift suggests that direct communication is a highly effective method for overcoming rejections with this examiner. Practitioners should consider an interview as a primary strategy for clarifying technical points and advancing the application toward a grant.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18561506 | EGFR TARGETING FC ANTIGEN BINDING FRAGMENT-DRUG CONJUGATES | Non-Final OA | MERCK PATENT GMBH |
| 17473401 | TREATMENT OF CANCER WITH HER2XCD3 BISPECIFIC ANTIBODIES IN COMBINATION WITH ANTI-HER2 MAB | Final Rejection | Genentech, Inc. |
| 17432868 | COMBINATION THERAPIES OF EGFRVIII CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | Final Rejection | Novartis AG |
| 18288241 | MODIFIED ORGANS AND TISSUES | Non-Final OA | UNIVERSITY HEALTH NETWORK |
| 17775543 | DOSAGE REGIMEN FOR ANTI-EGFRVIII AGENTS | Non-Final OA | AMGEN RESEARCH (MUNICH) GMBH |
| 18609772 | CYTOKINE ASSOCIATED TUMOR INFILTRATING LYMPHOCYTES COMPOSITIONS AND METHODS | Non-Final OA | Iovance Biotherapeutics, Inc. |
| 18560898 | PD-1 GENE-EDITED TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | Non-Final OA | Iovance Biotherapeutics, Inc. |
| 17050341 | CAR T CELLS WITH ONE OR MORE INTERLEUKINS | Final Rejection | Baylor College of Medicine |
| 16979396 | METHODS OF SELECTING T CELL LINE FOR ADOPTIVE CELLULAR THERAPY | Final Rejection | Memorial Sloan Kettering Cancer Center |
| 18547111 | Cation-Independent Mannose-6-Phosphate Receptor Binders | Non-Final OA | Universiteit Gent |
| 18548677 | T-CELLS FOR ANTI-HIV CAR-T THERAPY AND METHODS OF USE | Non-Final OA | City of Hope |
| 18005286 | NOVEL ANTI-PD1 ANTIBODIES FOR INHIBITING T-CELL ACTIVITY | Non-Final OA | THE CHILDREN'S MEDICAL CENTER CORPORATION |
| 18419527 | ANTIBODY THAT BINDS ERBB-2 AND ERBB-3 | Final Rejection | Merus N.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy